Anti-idiotypic reagents must be highly specific, sensitive and reproducible. Affimer technology meets these requirements for critical reagents in pharmacokinetic assays. Our new study highlights the development and validation of trastuzumab specific anti-idiotypic Affimer binders within a pharmacokinetic assay, showing that: